ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.
Eikon Therapeutics Inc. has received IND clearance from the FDA to initiate phase I studies with IMP-1734, a highly selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor developed in partnership with Impact Therapeutics Inc.
Precision Biosciences Inc. uses its proprietary Arcus platform to develop in vivo gene editing therapies and has outlined new data from its wholly owned and partnered pipeline.
Researchers from Michigan State University and Tarn Biosciences Inc. have published their work on the discovery and preclinical evaluation of novel antimycobacterial nitro-containing compounds.
Aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that maintains skin homeostasis in healthy skin and is expressed in keratinocytes, fibroblasts, mastocytes and melanocytes. In inflammatory skin disorders such as psoriasis, AhR deficit leads to marked skin inflammation, abnormal barrier function and increased cytokine release. Researchers from Sichuan University have reported the discovery and optimization of a new series of 2-thioxoimidazolidin-4-one derivatives acting as AhR agonists that led to the identification of [I] as the lead compound, which showed an EC50 value of 0.015 µM against AhR.
RSS
